Full Text View
Tabular View
No Study Results Posted
Related Studies
Risk Factors for Progressive Supranuclear Palsy (PSP)
This study is currently recruiting participants.
Verified by University of Louisville, August 2009
First Received: February 1, 2007   Last Updated: August 6, 2009   History of Changes
Sponsor: University of Louisville
Collaborator: National Institute on Aging (NIA)
Information provided by: University of Louisville
ClinicalTrials.gov Identifier: NCT00431301
  Purpose

Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.


Condition
Progressive Supranuclear Palsy

Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Genetic and Environmental Risk Factors for PSP

Resource links provided by NLM:


Further study details as provided by University of Louisville:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

DNA will be used for genotyping specific genes of interest related to the disease.


Estimated Enrollment: 1500
Study Start Date: August 2006
Estimated Study Completion Date: August 2010
Detailed Description:

This proposal will determine: (1) if there is an association between PSP and specific genes of interest; (2) if there is an association between PSP and occupational and/or environmental chemical exposures functionally or structurally similar to known parkinsonian toxicants; and (3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Understanding the etiology of PSP may also help explain the causes of other related diseases such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the etiology of PSP.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with clinically diagnosed Progressive Supranuclear Palsy and healthy controls

Criteria

Inclusion Criteria:

  • PSP patients able to visit one of the screening sites for diagnostic confirmation and able to participate in a one hour telephone interview

Exclusion Criteria:

  • No other major neurological disorders
  • Unable to communicate by telephone
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00431301

Contacts
Contact: Christopher Cunningham, Ph.D. 1-866-PSP-0448
Contact: Casey Shepherd, M.P.H. 1-866-PSP-0448

Locations
United States, Alabama
University of Alabama, Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Jennifer Newsome     205-996-7499        
Principal Investigator: David Standaert, M.D., Ph.D.            
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095-1759
Contact: Angeline Lo     310-206-2669        
Principal Investigator: Yvette Bordelon, M.D.            
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Katherine Howard, MS     303-724-2193        
Principal Investigator: Deborah Hall, MD            
United States, Florida
Mayo Clinic Jacksonville Withdrawn
Jacksonville, Florida, United States, 32224
United States, Georgia
Emory College of Medicine Recruiting
Atlanta, Georgia, United States, 30322
Contact: Carol Ingram     404-728-6859        
Principal Investigator: Jorge Juncos, M.D.            
United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40202
Contact: Chris Cunningham, Ph.D.     866-777-0448        
Contact: Casey Shepherd, M.P.H.     502-852-3655        
Principal Investigator: Irene Litvan, M.D.            
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States, 21201
Contact: Maura Deeley     410-328-7816        
Principal Investigator: Stephen Reich, M.D.            
United States, Ohio
Case Western University Recruiting
Cleveland, Ohio, United States, 44106
Contact: David Korosec     216-844-1800        
Principal Investigator: David Riley, M.D.            
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Christine Hunter     713-798-3951        
Principal Investigator: Joseph Jankovic, M.D.            
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98108
Contact: Anita Ranta     206-764-2339        
Principal Investigator: James Leverenz, MD            
Sponsors and Collaborators
University of Louisville
Investigators
Principal Investigator: Irene Litvan, M.D. University of Louisville
  More Information

Additional Information:
No publications provided

Responsible Party: University of Louisville ( Irene Litvan, MD, PI )
Study ID Numbers: 1 R01 AG024040-01A2, 1 R01 AG024040-01A2
Study First Received: February 1, 2007
Last Updated: August 6, 2009
ClinicalTrials.gov Identifier: NCT00431301     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by University of Louisville:
Progressive Supranuclear Palsy
Epidemiology
Case-Control
Genetic
Environmental
Neurodegenerative Disease
Movement Disorders
Atypical Parkinsonism
Parkinson Plus
Steele-Richardson-Olszewski
PSP

Additional relevant MeSH terms:
Eye Diseases
Basal Ganglia Diseases
Nervous System Diseases
Central Nervous System Diseases
Brain Diseases
Ophthalmoplegia
Neurodegenerative Diseases
Paralysis
Signs and Symptoms
Ocular Motility Disorders
Movement Disorders
Supranuclear Palsy, Progressive
Neurologic Manifestations
Cranial Nerve Diseases
Tauopathies

ClinicalTrials.gov processed this record on February 08, 2010